| Identification | Back Directory | [Name]
Hydrazinecarboximidamide, 2-[(2E)-3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-2-propen-1-ylidene]-, acetate (1:1), (2E)- | [CAS]
1809420-72-1 | [Synonyms]
Hydrazinecarboximidamide, 2-[(2E)-3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-2-propen-1-ylidene]-, acetate (1:1), (2E)- | [Molecular Formula]
C16H18N6O4 | [MOL File]
1809420-72-1.mol | [Molecular Weight]
358.36 |
| Hazard Information | Back Directory | [Uses]
Resomelagon (AP1189) acetate is a potent, orally active melanocortin receptor (MR) agonist about MC1 and MC3. Resomelagon acetate induces ERK1/2 phosphorylation and Ca2+ mobilization. Resomelagon acetate has anti-inflammatory activity. Resomelagon acetate can be used for obesity and chronic inflammation research[1][2]. | [in vivo]
Resomelagon acetate (0-10 mg/kg; i.p., i.v. and p.o.; for 24 h; male C57BL/6J wild-type (WT) and BALB/c mice) promotes resolution of acute inflammation in vivo[1].
Resomelagon acetate (25-50 mg/kg; p.o.; daily, for 8 d; male C57BL/6J wild-type (WT) and BALB/c mice) reduces arthritis in mice[1]. | [References]
[1] Montero-Melendez T, et, al. Biased agonism as a novel strategy to harness the proresolving properties of melanocortin receptors without eliciting melanogenic effects. J Immunol. 2015 Apr 1;194(7):3381-8. DOI:10.4049/jimmunol.1402645
[2] WHO Drug Information. International Nonproprietary Names for Pharmaceutical. |
|
|